88th European Atherosclerosis Society Congress 2020
More from ORION with inclirisan, siRNA therapeutic targeting the liver
EAS2020 reported new data for the efficacy of inclisiran in high-risk primary prevention patients from ORION 11. There were also findings from ORION-9 in heterozygous FH patients (1,2). ORION-11: Inclisiran is effective in high-risk primary prevention patients The ORION-11 study included 1,617 patients with either established…read more »
Long-term data with LIB003: where next for this PCSK9 inhibitor?
LIB003, a novel PCSK9 inhibitor given as a small volume monthly injection, was efficacious and well tolerated over 52 weeks. The results were reported at EAS2020- Virtual, 4-7 October (1). LIB003 is a recombinant fusion drug which combines a PCSK9-binding domain (adnectin) that blocks interaction…read more »
Evinacumab – answering an unmet need in homozygous FH?
A post hoc analysis from the ELIPSE HoFH study shows that homozygous familial hypercholesterolaemia (FH) patients with null LDLR mutations obtain about 50% reduction in LDL cholesterol on top of other therapy. The results were reported at EAS2020- Virtual, 4-7 October (1). Management of homozygous…read more »